

Additional Information – LR4.10.19

SYDNEY, Australia, 5 October 2022: Radiopharm Theranostics Limited (ASX:RAD or the “Company”) advises further to the previous quarterly activities reports released detailing the Company’s expenditure against the use of proceeds set out in its Prospectus. In accordance with LR 4.10.19, the Company has used the cash and assets in a form readily convertible to cash that it had at the time of admission to the Official List of ASX Limited on 23 November 2021, in a way that is consistent with its business objectives, during the period from admission to 30 June 2022.

Phillip Hains
Company Secretary